Ling Lin1, Baochun Lu1, Jianhua Yu1, Wenguang Liu2, Aijin Zhou3. 1. Department of General Surgery (Hepatobiliary Surgery), Shaoxing People's Hospital, Shaoxing, PR China; Shaoxing Hospital of Zhejiang University, Shaoxing 312000, Zhejiang Province, PR China. 2. Department of General Surgery, Linyi People's Hospital, Linyi 276000, Shandong Province, PR China. 3. Department of Emergency, Linyi People's Hospital, No. 27 Jiefang Road, Linyi 276000, Shandong Province, PR China. Electronic address: aijinzhouly@163.com.
Abstract
BACKGROUND AND OBJECTIVE: Circulating microRNAs (miRNAs) are known as potential noninvasive biomarkers for cancers. Overexpression of mircoRNA-224 (miR-224) has been reported in hepatocellular carcinoma (HCC), so the aim of this study was to determine the value of serum miR-224 in diagnosis of HCC at early stage. METHODS: Three hundred and thirty-five subjects including early-stage HCC, liver cirrhosis (LC), chronic hepatitis B (CHB) and healthy controls (HC) were enrolled in two cohorts. Association of miR-224 expression with HCC was analyzed. The area under curves (AUC) was calculated for miR-224 and compared with that for AFP in detection of HCC at early stage. RESULTS: Our results demonstrated that serum miR-224 was significantly higher in early-stage HCC than that in LC, CHB and HC, respectively. Besides, it decreased significantly after surgery in early-stage HCC, and there was a positive correlation between miR-224 in sera and that in paired tumor tissues. Serum miR-224 levels also showed a significant correlation with BCLC stages of HCC. Expression of miR-224 was significantly higher in tumorous tissues than that in adjacent non-tumorous tissues of HCC, pathologic liver tissues of LC and CHB. Further, ROC analysis demonstrated that AUC were 0.880 (95% CI: 0.838-0.923; sensitivity: 86.5%, specificity: 76.7%) for serum miR-224 in discriminating early-stage HCC from all three controls (LC, CHB and healthy subjects), higher than that for AFP (AUC: 0.700, 95% CI: 0.633-0.767; sensitivity: 71.9%, specificity: 63.7%) (P<0.01). Moreover, serum miR-224 also had a better performance than AFP in discriminating HCC from each of the three control groups. When miR-224 and AFP were used together, the diagnostic accuracy increased significantly compared with either marker alone. CONCLUSION: These results indicate that serum miR-224 is a potential reliable biomarker in detecting early-stage HCC, with better performance than AFP.
BACKGROUND AND OBJECTIVE: Circulating microRNAs (miRNAs) are known as potential noninvasive biomarkers for cancers. Overexpression of mircoRNA-224 (miR-224) has been reported in hepatocellular carcinoma (HCC), so the aim of this study was to determine the value of serum miR-224 in diagnosis of HCC at early stage. METHODS: Three hundred and thirty-five subjects including early-stage HCC, liver cirrhosis (LC), chronic hepatitis B (CHB) and healthy controls (HC) were enrolled in two cohorts. Association of miR-224 expression with HCC was analyzed. The area under curves (AUC) was calculated for miR-224 and compared with that for AFP in detection of HCC at early stage. RESULTS: Our results demonstrated that serum miR-224 was significantly higher in early-stage HCC than that in LC, CHB and HC, respectively. Besides, it decreased significantly after surgery in early-stage HCC, and there was a positive correlation between miR-224 in sera and that in paired tumor tissues. Serum miR-224 levels also showed a significant correlation with BCLC stages of HCC. Expression of miR-224 was significantly higher in tumorous tissues than that in adjacent non-tumorous tissues of HCC, pathologic liver tissues of LC and CHB. Further, ROC analysis demonstrated that AUC were 0.880 (95% CI: 0.838-0.923; sensitivity: 86.5%, specificity: 76.7%) for serum miR-224 in discriminating early-stage HCC from all three controls (LC, CHB and healthy subjects), higher than that for AFP (AUC: 0.700, 95% CI: 0.633-0.767; sensitivity: 71.9%, specificity: 63.7%) (P<0.01). Moreover, serum miR-224 also had a better performance than AFP in discriminating HCC from each of the three control groups. When miR-224 and AFP were used together, the diagnostic accuracy increased significantly compared with either marker alone. CONCLUSION: These results indicate that serum miR-224 is a potential reliable biomarker in detecting early-stage HCC, with better performance than AFP.
Authors: Merricka C Livingstone; Natalie M Johnson; Bill D Roebuck; Thomas W Kensler; John D Groopman Journal: Mol Carcinog Date: 2019-08-02 Impact factor: 4.784